Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial
Jin Li(Shanghai Cancer Institute), Shukui Qin(81th Hospital of PLA), Hongbing Wang(China University of Petroleum, East China), Ying Yuan(Zhejiang Cancer Hospital), Jianfeng Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongming Pan(Sir Run Run Shaw Hospital), Songhua Fan, Lin Shen(Peking University), Haihui Chen(Liuzhou Maternal and Child Health Hospital), Xiaojun Guo(China Banking Regulatory Commission), Yuxian Bai(Harbin Medical University), Ning Wang(Shanghai Ninth People's Hospital), Bin Zhang(Guangzhou University of Chinese Medicine), Donghui Chen(University of Washington), Zhuang Yu(Shanghai East Hospital), Tianshu Liu(Sun Yat-sen University), Shubin Wang(Hebei Medical University), Dong Ma, Haijun Zhong(Zhejiang Cancer Hospital), Jianming Xu(Chinese PLA General Hospital), Zhendong Chen(Anhui Medical University), Wei Li(Beijing Biocytogen (China)), Weijian Guo, Rubing Han(Shanghai Medical Information Center), Ying Cheng(First Affiliated Hospital of Xi'an Jiaotong University), Rui‐Hua Xu(Sun Yat-sen University), Yongqian Shu(Jiangsu Provincial Hospital of Traditional Chinese Medicine), Lei Yang(Nantong Tumor Hospital), Changping Wu(Soochow University), Sanyuan Sun(Xuzhou Central Hospital), Peiguo Cao(Central South University), Nong Xu(First Affiliated Hospital Zhejiang University), Yanhong Deng(Sun Yat-sen University)
Cited by 28
Related Papers
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k